An anticonvulsant used as an adjunct for managing partial onset seizures, postherpetic neuralgia and neuropathic pain associated with spinal cord injury and diabetic neuropathy, and fibromyalgia. It is structurally similar to gabapentin–Neurontin® but is more active against seizures. It is a Schedule V drug, with less CNS depressant activity than benzodiazepines.
Off-label uses Management of chronic pain, neuropathic pain, perioperative pain, migraine and generalised anxiety.
Adverse effects Somnolence, dizziness
Common adverse effects Blurred vision, diplopia, increased appetite, euphoria, confusion, vivid dreams, changed libido, irritability, ataxia, attention changes, abnormal coordination, memory impairment, tremors, dysarthria, paraesthesia, vertigo, dry mouth, constipation, vomiting, flatulence, erectile dysfunction, fatigue, peripheral oedema, weight gain, asthenia, nasopharyngitis, increased creatine kinase.
In 2009, Pfizer pled guilty to misbranding Lyrica “with the intent to defraud or mislead“, resulting in a $2.3 bn settlement.
Proprietary names Lyrica, Serigaptin